About Us - Drug Development Technology

Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Advertise with us

APIs

Vaccine development: the need for speed

Lack of CMO availability threatens cell and gene therapy development

Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye

Approvals

US biosimilar setbacks highlight difficulty of cost-effective development

POINT trial may increase clopidogrel use in secondary ischemic stroke prevention

FDA approves first non-opioid treatment for opioid withdrawal

Clinical Research

US biosimilar setbacks highlight difficulty of cost-effective development

PD-L1 biomarker makes a comeback in bladder cancer

POINT trial may increase clopidogrel use in secondary ischemic stroke prevention

Clinical Trials

Bionomics begins Phase II trial of BNC210 to treat agitation

Merus doses first patient in Phase I trial of MCLA-158

NIH starts Phase l trial of mAb114 to treat Ebola

Diseases

PD-L1 biomarker makes a comeback in bladder cancer

CBD shown to reduce number of seizures in epilepsy patients

Cell recycling process could treat neurodegenerative conditions

Genomics & Proteomics

Oncology: the ups and downs of enrollment in China

AACR 2018: revisiting murine models to develop drug combos for KRAS-driven cancers

Lack of CMO availability threatens cell and gene therapy development

Market Data

US biosimilar setbacks highlight difficulty of cost-effective development

Phase II most common among immuno-oncology trials, 2008-2017

Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

Technology

Emulate and AstraZeneca announce Organs-on-Chips partnership

LIDDS verifies NanoZolid for controlled release of cancer drugs

Merck’s Keytruda combo could be a winner for NSCLC and other solid tumours

Online

Read more

In Print

Read more